Express Pharma Granules India gets licence from DRDO to manufacture and market COVID-19 drug 2-DG

Granules India said on Thursday that it has received licence from Defence Research and Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.

“Granules is working closely with DRDO team to launch the product in India at the earliest,” it added.

The drug reduces a patient’s average recovery time by two and half days and oxygen demand by up to 40 per cent, the filing said.

Medically Speaking Team

Recent Posts

THE HIDDEN CHALLENGE OF WEIGHT LOSS: HOW FAT CELLS “REMEMBER” OBESITY

Losing weight is a significant milestone, but for many, the bigger battle lies in keeping…

16 hours ago

LINDT CHOCOLATE CONTROVERSY: HEAVY METALS DISCOVERED IN POPULAR BRAND’S PRODUCTS

In recent months, a growing controversy has surfaced regarding the presence of heavy metals—specifically lead…

17 hours ago

THE SURPRISING BENEFITS OF VITAMIN B3 IN LOWERING DEATH RISK AND IMPROVING HEART HEALTH

A new study published in Scientific Reports has shed light on the potential benefits of dietary…

18 hours ago

WOMEN’S HEALTH: HOW EXCESS ZINC CAN DISRUPT MENSTRUAL CYCLE AND FERTILITY

Zinc is an essential mineral that plays a crucial role in maintaining overall health. Known…

19 hours ago

AIIMS- LED TRIAL FINDS OPTIMAL DRUG COMBINATION FOR HYPERTENSION PATIENTS

A groundbreaking clinical trial, spearheaded by a team of Indian and international experts, has shed…

20 hours ago

LINK BETWEEN COVID-19 INFECTION AND CANCER REGRESSION UNCOVERED IN A GROUNDBREAKING DISCOVERY

In an unprecedented discovery, scientists have uncovered a surprising connection between COVID-19 infections and the…

21 hours ago